FDA's Generic Approvals Catch A Bit Of Breath In July But Continue At Fast Pace

US Generic drug approvals drop in July, but still are above the monthly average for the year, potentially signaling a new expected output.

FDA's July generic drug approvals tally did not repeat its June record-breaking performance, but the agency still is working at an elevated pace.

That's particularly encouraging news for stakeholders as the agency next month marks its first 10-month approval goal deadline under the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Already a subscriber?